Trial reportInternational journal of radiation oncology, biology, physics2012
Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients.
Trial report in International journal of radiation oncology, biology, physics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 113 citations in OpenAlex.
- Radiation-induced remodeling of the T cell landscape in head and neck cancer.Cancer immunology, immunotherapy : CII · 2026Review
- Review
- Radiation-induced tumor immune microenvironments and potential targets for combination therapy.Signal transduction and targeted therapy · 2023Review
- Application of nanotechnology in reversing therapeutic resistance and controlling metastasis of colorectal cancer.World journal of gastroenterology · 2023Review
- Current research and management of undifferentiated pleomorphic sarcoma/myofibrosarcoma.Frontiers in genetics · 2023Review
- Image-guided intratumoral immunotherapy: Developing a clinically practical technology.Advanced drug delivery reviews · 2022Review
- Survival comparison between postoperative and preoperative radiotherapy for stage I-III non-inflammatory breast cancer.Scientific reports · 2022Article
- How to Improve SBRT Outcomes in NSCLC: From Pre-Clinical Modeling to Successful Clinical Translation.Cancers · 2022Review
- Enhancing anti-tumour innate immunity by targeting the DNA damage response and pattern recognition receptors in combination with radiotherapy.Frontiers in oncology · 2022Review
- ATRX Alteration Contributes to Tumor Growth and Immune Escape in Pleomorphic Sarcomas.Cancers · 2021Article
- The Lymph-Sparing Quotient: A Retrospective Risk Analysis on Extremity Radiation for Soft Tissue Sarcoma Treatment.Cancers · 2021Article
- Charged Particle and Conventional Radiotherapy: Current Implications as Partner for Immunotherapy.Cancers · 2021Review
- Review
- Roles of Neutrophils in Glioma and Brain Metastases.Frontiers in immunology · 2021Review
- The Role of Radiotherapy in Soft Tissue Sarcoma on Extremities With Lymph Nodes Metastasis: An IPTW Propensity Score Analysis of the SEER Database.Frontiers in oncology · 2021Article
- Reprogramming the tumour microenvironment by radiotherapy: implications for radiotherapy and immunotherapy combinations.Radiation oncology (London, England) · 2020Review
- Intratumoral Immunotherapy for Early-stage Solid Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Review
- The tumour microenvironment of the upper and lower gastrointestinal tract differentially influences dendritic cell maturation.BMC cancer · 2020Article
- Immunotherapy in soft-tissue sarcoma.Current oncology (Toronto, Ont.) · 2020Review
- Dendritic Cell-Based Immunotherapy in Lung Cancer.Frontiers in immunology · 2020Review
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 1 institution in 1 country.
Funding
Abstract
purposeThe goal of this study was to determine the effect of combination of intratumoral administration of dendritic cells (DC) and fractionated external beam radiation (EBRT) on tumor-specific immune responses in patients with soft-tissue sarcoma (STS). METHODS AND MATERIAL: Seventeen patients with large (>5 cm) high-grade STS were enrolled in the study. They were treated in the neoadjuvant setting with 5,040 cGy of EBRT, split into 28 fractions and delivered 5 days per week, combined with intratumoral injection of 10(7) DCs followed by complete resection. DCs were injected on the second, third, and fourth Friday of the treatment cycle. Clinical evaluation and immunological assessments were performed.
resultsThe treatment was well tolerated. No patient had tumor-specific immune responses before combined EBRT/DC therapy; 9 patients (52.9%) developed tumor-specific immune responses, which lasted from 11 to 42 weeks. Twelve of 17 patients (70.6%) were progression free after 1 year. Treatment caused a dramatic accumulation of T cells in the tumor. The presence of CD4(+) T cells in the tumor positively correlated with tumor-specific immune responses that developed following combined therapy. Accumulation of myeloid-derived suppressor cells but not regulatory T cells negatively correlated with the development of tumor-specific immune responses. Experiments with (111)In labeled DCs demonstrated that these antigen presenting cells need at least 48 h to start migrating from tumor site.
conclusionsCombination of intratumoral DC administration with EBRT was safe and resulted in induction of antitumor immune responses. This suggests that this therapy is promising and needs further testing in clinical trials design to assess clinical efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.